BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS MARKET ANALYSIS BY TYPE, APPLICATION, REGIONS AND COMPANIES FORECAST

  2024-11-27 |   Pages: 200+ |   Report ID: MD-R-2024-11-27-88819 |   Healthcare

Historical data: 2018 - 2023

Forecast period: 2024 - 2031

Quantitative units: Revenue in USD million and CAGR from 2024 to 2031

Report coverage: Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Benign Prostatic Hyperplasia (BPH) Drugs Market

Image

1.1 SCOPE OF THE REPORT

1.2 MARKET SEGMENT ANALYSIS

1.3 REGULATORY SCENARIO BY REGION/COUNTRY

1.4 MARKET INVESTMENT SCENARIO STRATEGIC

1.5 MARKET ANALYSIS BY TYPE (USD MILLION)

1.6 MARKET ANALYSIS BY APPLICATION (USD MILLION)

2.1 DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS

  2.1.1 MARKET DRIVER ANALYSIS

  2.1.2 MARKET RESTRAINT ANALYSIS

  2.1.3 MARKET OPPORTUNITY

  2.1.4 MARKET CHALLENGES

3.1 INDUSTRY TRENDS

  3.1.1 SWOT ANALYSIS

  3.1.2 PESTEL ANALYSIS

  3.1.3 PORTER’S FIVE FORCES ANALYSIS

3.2 POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS

4.1 COVID-19 ANALYSIS

5.1 GLOBAL BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS MARKET, SALES AREA, TYPE

5.2 MERGERS & ACQUISITIONS, PARTNERSHIPS, PRODUCT LAUNCH, AND COLLABORATION IN GLOBAL BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS MARKET

7.1 GLOBAL BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS MARKET SIZE AND SHARE (2018-2031) (USD MILLION)

8.1 GLOBAL BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

8.2 GLOBAL BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

9.1 GLOBAL BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

9.2 GLOBAL BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

10.1 GLOBAL BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS MARKET SIZE AND SHARE BY REGION (2018-2023) (USD MILLION)

10.2 GLOBAL BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS MARKET SIZE AND SHARE BY REGION (2024-2031) (USD MILLION)

11.1 NORTH AMERICA BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

11.2 NORTH AMERICA BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

11.3 NORTH AMERICA BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

11.4 NORTH AMERICA BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

11.5 NORTH AMERICA BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

11.6 NORTH AMERICA BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

12.1 EUROPE BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

12.2 EUROPE BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

12.3 EUROPE BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

12.4 EUROPE BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

12.5 EUROPE BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

12.6 EUROPE BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

13.1 ASIA PACIFIC BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

13.2 ASIA PACIFIC BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

13.3 ASIA PACIFIC BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

13.4 ASIA PACIFIC BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

13.5 ASIA PACIFIC BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

13.6 ASIA PACIFIC BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

14.1 LATIN AMERICA BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)/p>

14.2 LATIN AMERICA BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

14.3 LATIN AMERICA BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

14.4 LATIN AMERICA BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

14.5 LATIN AMERICA BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

14.6 LATIN AMERICA BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

15.1 MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

15.2 MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

15.3 MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

15.4 MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

15.5 MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

15.6 MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS MARKET SIZE AND SHARE BY APPLICATION (2024-2031)< (USD MILLION)/p>

16.1 Astellas Pharma

  16.1.1 COMPANY DETAILS

  16.1.2 FINANCIALS (USD MILLION)

  16.1.3 PRODUCT SUMMARY

  16.1.4 RECENT DEVELOPMENTS

16.2 Eli Lilly

16.3 GlaxoSmithKline

16.4 Sanofi

16.5 ADC Therapeutics

16.6 Bayer HealthCare

16.7 Bristol-Myers Squibb

16.8 Valeant Pharmaceuticals

16.9 Endo Pharmaceuticals

16.10 Foresee Pharmaceuticals

16.11 Madrigal Pharmaceuticals

16.12 Merck

16.13 Novartis

16.14 Spectrum Pharmaceuticals

16.15 Takeda Pharmaceuticals

16.16 Teva

16.17 Advaxis

16.18 ANI Pharmaceuticals

16.19 BHR Pharma

18.1 METHODOLOGY

18.2 RESEARCH DATA SOURCE

  18.2.1 SECONDARY DATA

  18.2.2 KEY DATA FROM SECONDARY

  18.2.3 PRIMARY DATA

  18.2.4 KEY DATA FROM PRIMARY

  18.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS

  18.2.6 MARKET ESTIMATION

  18.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH

  18.2.8 LEGAL DISCLAIMER

Market Segments

Market By Type
- Alpha-blocker
- Phosphodiesterase Type-5 Inhibitors
- 5-alpha-Reductase Inhibitors

Based on the end-use, the global Benign Prostatic Hyperplasia (BPH) Drugs market classified into
- Hospitals
- Clinics
- Others

Companies

Astellas Pharma
Eli Lilly
GlaxoSmithKline
Sanofi
ADC Therapeutics
Bayer HealthCare
Bristol-Myers Squibb
Valeant Pharmaceuticals
Endo Pharmaceuticals
Foresee Pharmaceuticals
Madrigal Pharmaceuticals
Merck
Novartis
Spectrum Pharmaceuticals
Takeda Pharmaceuticals
Teva
Advaxis
ANI Pharmaceuticals
BHR Pharma

Single User License  : 3900$
Corporate License    : 7800$
Enquiry Before Buying
Request For Customization
Speak To Analyst

BROWSE INDUSTRY

  1. Consumer Goods
  2. Healthcare
  3. Food & Beverage
  4. Heavy Industry
  5. Service Industries
  6. FMCG
  7. Life Sciences
  8. Technology & Media
  9. Machinery & Equipment

    WHY CHOOSE US

  •   PROACTIVE

    • We manage our resources 24/7 to identify issues and address them before they become problems.

  •   QUALITY & RELIABILITY

    • We are committed to providing reliable and highly accurate data with an excellent quality control system.

  •   GLOBAL OUTREACH

    • 6 Major regions and 40+ countries level analysis accomplished.

  •   COMPETITIVE PRICING

    • Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery.